Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Nxera Hits Important Milestone in Diabetes Drug Partnership with Eli Lilly | 9 | Insider Monkey | ||
Di | Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 | 67 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 3 June 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that its partner, Neurocrine Biosciences ("Neurocrine") has dosed the first... ► Artikel lesen | |
Mo | Nxera Pharma Reaches Key Milestone In Lilly Partnership For Diabetes & Metabolic Disease Research | 433 | AFX News | INDIANAPOLIS (dpa-AFX) - Nxera Pharma Co., Ltd. announced that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly and Co. (LLY)... ► Artikel lesen | |
Mo | Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases | 110 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 2 June 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that it has achieved a development milestone under its multi-target collaboration... ► Artikel lesen | |
02.05. | Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025 | 120 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 2 May 2025 - Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter... ► Artikel lesen | |
01.05. | Nxera Pharma's Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia | 141 | GlobeNewswire (Europe) | NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with NeurocrineFor more information... ► Artikel lesen | |
NXERA PHARMA Aktie jetzt für 0€ handeln | |||||
01.05. | Nxera Pharma Appoints Top-Ranked Biopharma Investment Analyst Shinya Tsuzuki as Head of Investor Relations | 1 | GlobeNewswire (USA) | ||
03.04. | Nxera Pharma appoints AstraZeneca alum as inaugural commercial chief | 3 | FiercePharma | ||
01.04. | Nxera Pharma Announces Appointments to its Executive Leadership Team | 1 | GlobeNewswire (USA) | ||
25.03. | Nxera Pharma's Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder | 274 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 25 March 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) announces that its partner Tempero Bio, Inc. has initiated a Phase 2 trial of TMP-301, a... ► Artikel lesen | |
28.02. | Nxera sells APAC license to lupus drug to Viatris for $10M upfront | 32 | FierceBiotech | ||
28.02. | Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan | 1 | GlobeNewswire (USA) | ||
28.02. | Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris | 30 | GlobeNewswire (USA) | ||
14.02. | Nxera Pharma Proposes Changes to its Board of Directors | 1 | GlobeNewswire (USA) | ||
14.02. | Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2024 | 341 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 14 February 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) provides an update on operational activities and reports its consolidated results for... ► Artikel lesen | |
07.02. | Singtel's Nxera DCT bags $643m green loan for new data centre in Tuas | 2 | Singapore Business Review | ||
23.01. | Nxera Pharma Webinar Presentation for FY2024 Financial Results | 3 | GlobeNewswire (USA) | ||
14.01. | Nxera Pharma Provides Update on Neurocrine's Progress with its Partnered Muscarinic Agonist Portfolio | 11 | GlobeNewswire (USA) | ||
19.12.24 | Nxera Pharma and Shionogi Launch QUVIVIQ in Japan for Adults with Insomnia | 14 | GlobeNewswire (USA) | ||
05.12.24 | Nxera Pharma Enrolls First Insomnia Patient in its Phase 3 Clinical Trial of Daridorexant in South Korea | 181 | GlobeNewswire (Europe) | Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomniaQUVIVIQ (daridorexant) 25 and 50 mg was recently approved and is expected... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PFIZER | 20,560 | +0,22 % | BERENBERG stuft PFIZER INC auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Pfizer von 28 auf 25 US-Dollar gesenkt und die Einstufung auf "Hold" belassen. Da neue Medikamente die Einbußen durch das Auslaufen... ► Artikel lesen | |
NOVARTIS | 103,06 | +0,45 % | Märkte am Morgen: Lanxess, Öl, Roche, Novartis, Rheinmetall, Hensoldt, Renk | Der Mai gilt eigentlich als schlechter Börsenmonat. In diesem Jahr wurde er seinem Ruf allerdings nicht gerecht. Der DAX legte im Mai 6,7 Prozent zu, mehrere Allzeithochs inklusive. Heute dürfte der... ► Artikel lesen | |
GILEAD SCIENCES | 95,72 | +0,18 % | Gilead Sciences Commemorated the Opening of the Bay Area Young Survivors Breast Cancer Memorial Garden | NORTHAMPTON, MA / ACCESS Newswire / May 30, 2025 / Gilead Sciences:We recently commemorated the opening of the Bay Area Young Survivors Breast Cancer Memorial Garden in San Francisco's Golden Gate Park.... ► Artikel lesen | |
SANOFI | 87,54 | +0,74 % | Aktienmarkt: Kurs der Sanofi SA-Aktie im Minus (92,27 €) | Im Minus liegt gegenwärtig der Anteilsschein von Sanofi SA . Die Aktie kostete zuletzt 92,27 Euro. An der Börse liegt die Aktie von Sanofi SA derzeit im Minus. Das Papier verbilligte sich um 25 Cent.... ► Artikel lesen | |
ABBVIE | 164,40 | +0,12 % | ASCO25: AbbVie flexes ADC Phase I data as NSCLC market opportunity beckons | ||
ROCHE | 287,60 | +0,31 % | DEUTSCHE BANK RESEARCH stuft ROCHE HOLDINGS AG auf 'Sell' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Roche nach einer Investorenveranstaltung zum Diagnostik-Geschäft auf "Sell" mit einem Kursziel von 250 Franken belassen.... ► Artikel lesen | |
ABBOTT LABORATORIES | 116,40 | -0,10 % | Pressmaster DMCC: Veteran-Owned Nate Woodard Acquires Abbotts Uniforms, Continuing Legacy of Excellence in Military and Uniformed Servicewear | Quantico, Virginia--(Newsfile Corp. - June 4, 2025) - Nate Woodard, a veteran-owned small business known for its commitment to craftsmanship and service, is proud to announce the acquisition of Abbott... ► Artikel lesen | |
HAEMATO | 11,300 | 0,00 % | M1 Kliniken: Verkauf von HAEMATO PHARM im Fokus | Die M1 Kliniken AG steht vor dem möglichen Verkauf eines Teils der Konzern-Aktivitäten: Die zur Gruppe gehörende HAEMATO AG prüft derzeit ein verbindliches Angebot für den Verkauf ihrer Tochtergesellschaft... ► Artikel lesen | |
INCYTE | 59,06 | -0,03 % | Incyte kündigt mehrere Präsentationen an, darunter neue aktuelle Daten zu seinem mutCALR-gerichteten monoklonalen Antikörper (INCA033989), die zur Präsentation auf der EHA 2025 angenommen wurden | In einer Late-Breaking mündlichen Präsentation werden neue Daten aus einer Studie mit INCA033989 vorgestellt, einem gegen mutiertes Calreticulin (mutCALR) gerichteten monoklonalen Antikörper... ► Artikel lesen | |
EDWARDS LIFESCIENCES | 67,41 | -0,46 % | Edwards Lifesciences Corporation: Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes | Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing... ► Artikel lesen | |
WPD PHARMACEUTICALS | 0,002 | 0,00 % | CSE Bulletin: Consolidation - WPD Pharmaceuticals Inc. (WBIO) | le 23 décembre/December 2024
WPD Pharmaceuticals Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every twenty-five... ► Artikel lesen | |
HALEON | 4,802 | 0,00 % | Haleon plc gibt Update zu Aktienbesitz eines Direktors bekannt | ||
BIONANO GENOMICS | 3,700 | 0,00 % | Bionano Genomics: Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress | SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2025. "The first quarter of 2025 represents... ► Artikel lesen | |
TONIX PHARMACEUTICALS | 34,200 | 0,00 % | Tonix Pharmaceuticals Holding Corp. - S-8, Securities to be offered to employees in employee benefit plans | ||
GRIFOLS | 10,290 | +3,50 % | Mason Capital Management LLC: Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting | Believes Board Leadership Continuity and Continued Management Focus and Execution Will Drive Long-Term Shareholder Value
Mason Capital Management LLC ("Mason"), a registered investment advisor... ► Artikel lesen |